Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.95 |
| ▸ | CPT2 | P23786 | 2/20 | 0.59 |
| ▸ | CPT1A | P50416 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | CRAT | P43155 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levocarnitine SCHEMBL21970 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| D-Carnitine SCHEMBL94286 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL21971 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL1813524 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL3902633 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL4593172 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL17629811 | 0.98 | SLC22A16 (1.00) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Levocarnitine SCHEMBL23249739 | 0.95 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL8389713 | 0.95 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 | |
| Carnitine SCHEMBL357560 | 0.95 | SLC22A16 (0.95) | SLC22A16CPT2CPT1AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116762936-A | Production method of konjaku flour L-carnitine chromium yeast particles | 安徽金源药业有限公司 | 2023-09-19 | — | — | CN | claimed |
| US-20080114065-A1 | Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology | BIONEXUS, LTD. | 2008-05-15 | — | — | US | claimed |
| US-20040106591-A1 | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia | BIONEXUS, LTD. | 2004-06-03 | — | — | US | claimed |
| US-6733793-B2 | DIETARY SUPPLEMENT; VANADYL SULFATE, ALPHA-LIPOIC ACID, TAURINE, AND CHROMIUM CARNITINE; NORMALIZATION OF INSULIN ACTIVITY IN DIABETICS AND NON-DIABETICS | METAPROTEOMICS, LLC | 2004-05-11 | — | — | US | claimed |
| WO-2003101469-A1 | AN ORAL COMPOSITION WITH INSULIN-LIKE ACTIVITIES AND METHODS OF USE | METAPROTEOMICS, LLC (US) | 2003-12-11 | — | — | WO | claimed |
| US-20030224061-A1 | Oral composition with insulin-like activities and methods of use | META PROTEOMICS, LLC | 2003-12-04 | — | — | US | claimed |
| CN-116762936-A | Production method of konjaku flour L-carnitine chromium yeast particles | 安徽金源药业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116762936-A | Production method of konjaku flour L-carnitine chromium yeast particles | 安徽金源药业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116762936-A | Production method of konjaku flour L-carnitine chromium yeast particles | 安徽金源药业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-8642651-B2 | Methods and compositions for improved chromium complexes | VDF FUTURECEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8093292-B2 | Conjugated fatty acid or alcohol, thiol-containing compound and bioavailable form of trivalent chromium; preventing metabolic dysregulation of adipocytes resulting from HIV-1 infection or chronic inflammation | BIONEXUS, LTD. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110263702-A1 | Methods and Compositions for Improved Chromium Complexes | MILJKOVIC DUSAN | 2011-10-27 | — | — | US | disclosed |
| US-8017651-B2 | Conjugated fatty acid or alcohol, thiol-containing compound and bioavailable form of trivalent chromium | BIONEXUS, LTD. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20040106591-A1 | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia | BIONEXUS, LTD. | 2004-06-03 | — | — | US | disclosed |
| US-6733793-B2 | DIETARY SUPPLEMENT; VANADYL SULFATE, ALPHA-LIPOIC ACID, TAURINE, AND CHROMIUM CARNITINE; NORMALIZATION OF INSULIN ACTIVITY IN DIABETICS AND NON-DIABETICS | METAPROTEOMICS, LLC | 2004-05-11 | — | — | US | disclosed |
| US-6733793-B2 | DIETARY SUPPLEMENT; VANADYL SULFATE, ALPHA-LIPOIC ACID, TAURINE, AND CHROMIUM CARNITINE; NORMALIZATION OF INSULIN ACTIVITY IN DIABETICS AND NON-DIABETICS | METAPROTEOMICS, LLC | 2004-05-11 | — | — | US | disclosed |
| WO-2003101469-A1 | AN ORAL COMPOSITION WITH INSULIN-LIKE ACTIVITIES AND METHODS OF USE | METAPROTEOMICS, LLC (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101469-A1 | AN ORAL COMPOSITION WITH INSULIN-LIKE ACTIVITIES AND METHODS OF USE | METAPROTEOMICS, LLC (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030224061-A1 | Oral composition with insulin-like activities and methods of use | META PROTEOMICS, LLC | 2003-12-04 | — | — | US | disclosed |
| US-20030224061-A1 | Oral composition with insulin-like activities and methods of use | META PROTEOMICS, LLC | 2003-12-04 | — | — | US | disclosed |